Genzyme Tissue biomaterial/skin/wound news

GENZL said that it will refocus and reduce R&D spending, including shifting its Carticel research away from second generation discovery to the development of instrumentation that the company said will create a faster, less invasive procedure. The Carticel process cultures and implants cartilage cells based on an autologous chondrocyte implantation procedure.

GENZL also said it is seeking a partner for its TGF-beta compound to treat chronic skin ulcers, which is in Phase II trials. ...